Related Experiment Video
Updated: May 12, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Management of status asthmaticus in children
Muriel Koninckx1, Corinne Buysse, Matthijs de Hoog
1Paediatric Intensive Care, Middelheim Ziekenhuis, Lindendreef 1, Antwerp, Belgium. murielkoninckx@gmail.com
Insights
Paediatric status asthmaticus (PSA) is a life-threatening emergency requiring prompt intervention. Current diagnostic tools are unreliable, highlighting the need for better assessment methods and optimized treatment strategies for severe asthma attacks in children.
Area of Science:
- Pediatric Intensive Care
- Pulmonology
- Emergency Medicine
Background:
- Paediatric status asthmaticus (PSA) admissions to pediatric intensive care units are increasing.
- PSA is a potentially fatal medical emergency requiring immediate and careful management.
- Current methods for assessing PSA severity, such as peak flow and lung function tests, lack reliability.
Purpose of the Study:
- To review the current understanding of paediatric status asthmaticus.
- To highlight the limitations in current diagnostic and assessment tools for PSA.
- To outline optimal treatment strategies addressing the key pathophysiological factors of PSA.
Main Methods:
- Literature review focusing on recent findings in paediatric status asthmaticus.
- Analysis of the pathophysiology of PSA, including bronchoconstriction, mucus plugging, and airway inflammation.
- Compilation of current and additional treatment modalities for managing severe paediatric asthma.
Main Results:
- Clinical judgment remains the primary method for assessing PSA severity.
- Validated, clinically useful instruments for assessing PSA are currently lacking.
- Effective treatment requires addressing bronchoconstriction, mucus plugging, and inflammation.
Conclusions:
- There is an increasing trend of PSA admissions, emphasizing its critical nature.
- Improved diagnostic and assessment tools are needed for reliable evaluation of PSA severity.
- Optimized treatment involves addressing multiple pathophysiological aspects and considering various therapeutic options.
Abstract:
Recent literature on paediatric status asthmaticus (PSA) confirms an increasing percentage of admissions to paediatric intensive care units. PSA is a medical emergency that can be fatal and needs careful and prompt intervention. The severity of PSA is mainly determined by clinical judgement of signs and symptoms. Peak flow measurements and serial lung function measurements are not reliable in PSA. Validated clinically useful instruments are lacking. The three main factors that are involved in the pathophysiology of PSA, bronchoconstriction, mucus plugging and airway inflammation need to be addressed to optimise treatment. Initial therapies include supplementation of oxygen, repetitive administration of rapid acting β2-agonists, inhaled anticholinergics in combination with systemic glucocorticosteroids and intravenous magnesium sulphate. Additional treatment modalities may include methylxanthines, DNase, ketamine, sodium bicarbonate, heliox, epinephrine, non-invasive respiratory support, mechanical ventilation and inhalational anaesthetics.
Related Concept Videos
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management
First, in...
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...